Drugs / Rintatolimod
Rintatolimod
also known as
Ampligen · Poly I: Poly C12U · atvogen · poly-l:poly-C12U · rintatolimod (Ampligen) · Rintatolimod (poly I : poly C12U)
Oligonucleotide (other) targets TLR3 via activation
Trials 28
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03599453 | Jan 2019 → Sep 2020 | triple-negative breast carcinoma | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT04081389 | Dec 2019 → May 2022 | breast carcinoma in situ, triple-negative breast carcinoma | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT00000735 | ? → Feb 1990 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00000713 | ? → Oct 1992 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/210 trials | ||||||
| Phase 1/2 | NCT05756166 | Feb 2024 → Apr 2025 | female breast carcinoma, triple-negative breast carcinoma | Roswell Park Cancer Institute | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT05927142 | Jan 2024 → Dec 2026 expected | pancreatic ductal adenocarcinoma | Joachim Aerts, MD PhD | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04379518 | Nov 2020 → Mar 2023 | COVID-19, cancer, hematopoietic and lymphoid cell neoplasm | Roswell Park Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03734692 | Jan 2019 → Jul 2024 overdue | ovarian carcinoma | Robert Edwards | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02432378 | Sep 2015 → Jun 2025 | ovarian cancer | Roswell Park Cancer Institute | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02151448 | Jul 2014 → Feb 2019 | malignant pancreatic neoplasm, malignant peritoneal mesothelioma, peritoneal carcinomatosis | David Bartlett | Completed | No outcome recorded |
| Phase 1/2 | NCT01545141 | Oct 2012 → Apr 2016 | colorectal carcinoma | Roswell Park Cancer Institute | Terminated | No outcome recorded |
| Phase 1/2 | NCT01591473 | Apr 2012 → Sep 2014 | influenza | AIM ImmunoTech Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT01355393 | Jul 2011 → Nov 2013 | HER2 positive breast carcinoma, male breast carcinoma | University of Washington | Completed | No outcome recorded |
| Phase 1/2 | NCT01312389 | Apr 2011 → May 2012 | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Abramson Cancer Center at Penn Medicine | Terminated | No outcome recorded |
| Phase 210 trials · 1 missed | ||||||
| Phase 2 | NCT07634094 | Aug 2026 → Aug 2028 expected | ovarian cancer | Kalinski, Pawel, MD, PhD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05494697 | Jun 2026 → Dec 2029 | malignant pancreatic neoplasm | AIM ImmunoTech Inc. | Suspended | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04093323 | Nov 2024 → Apr 2025 | — | Roswell Park Cancer Institute | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT05592418 | Jun → Nov 2023 | long COVID-19 | AIM ImmunoTech Inc. | Completed | Missed primary |
| Phase 2 | NCT04119830 | Feb 2022 → Feb 2024 | colorectal adenocarcinoma | Roswell Park Cancer Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT03899987 | Nov 2019 → Apr 2027 expected | prostate adenocarcinoma | Roswell Park Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03403634 | Apr 2018 → Dec 2020 | colorectal carcinoma, metastatic carcinoma | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT02615574 | Mar 2016 → Jun 2018 | colorectal cancer | Pawel Kalinski | Withdrawn | No outcome recorded |
| Phase 2 | NCT00035893 | May 2001 → Aug 2006 | HIV infectious disease | AIM ImmunoTech Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00035581 | May 2001 → Sep 2005 | HIV infectious disease | AIM ImmunoTech Inc. | Terminated | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT00215800 | Dec 1998 → Feb 2004 | myalgic encephalomeyelitis/chronic fatigue syndrome | AIM ImmunoTech Inc. | Completed | Met primary |
| Phase not applicable2 trials | ||||||
| — | NCT00002269 | — | HIV infectious disease | HEM Research | Completed | No outcome recorded |
| — | NCT00001000 | ? → Jan 1990 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT00215813 | — | myalgic encephalomeyelitis/chronic fatigue syndrome | AIM ImmunoTech Inc. | Temporarily not available | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 29 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rintatolimod | “Patients were enrolled in phase I portion of the trial NCT02432378, and treated with intraperitoneal cisplatin, intraperitoneal rintatolimod (dsRNA, TLR3 ligand), and oral...” PMID 35046055 ↗ May 202218“The study drugs are a combination of celecoxib (Celebrex®), Interferon-α2b (IFN), and rintatolimod (Ampligen®), or CKM.” NCT02615574 ↗ “rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery” NCT01545141 ↗ |
| Known as | Ampligen | “The study drugs are a combination of celecoxib (Celebrex®), Interferon-α2b (IFN), and rintatolimod (Ampligen®), or CKM.” NCT02615574 ↗ |
| Known as | atvogen | “a single dose of atvogen (ampligen)” NCT00001000 ↗ |
| Known as | Poly I: Poly C12U | “poly I:poly C12U (Ampligen®) 400 mg IV Twice Weekly Versus Placebo” NCT00215800 ↗ |
| Known as | poly-l:poly-C12U | “Ampligen (poly-l:poly-C12U), a Toll-like receptor 3 agonist.” NCT01312389 ↗ |
| Known as | rintatolimod (Ampligen) | “rintatolimod (Ampligen®)” NCT02615574 ↗ |
| Known as | Rintatolimod (poly I : poly C12U) | “Rintatolimod (poly I : poly C12U)” NCT05592418 ↗ |
| Action | Inhibit | “In vitro studies of ampligen have shown it will inhibit HIV infection.” NCT00001000 ↗ |
| Modality | Oligonucleotide (other) | “rintatolimod (dsRNA, TLR3 ligand)” PMID 35046055 ↗ May 2022 |
| Route | Intravenous | “given ampligen by intravenous infusion” NCT00000713 ↗ |
| Target | TLR3 | “selective TLR3 agonist” PMID 33119613 ↗ Oct 2020 |